ArticleChemical biology & drug design2026
An Integrative Methylation-Metabolism Gene Signature Defines Prognosis and Immunosuppressive Microenvironment in Prostate Cancer.
Article in Chemical biology & drug design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The synergistic crosstalk between epigenetic dysregulation and metabolic reprogramming underlies to prostate cancer (PCa) development and treatment resistance, yet an integrated prognostic signature reflecting this nexus remains poorly defined. We developed and validated a gene signature associated with methylation and amino acid metabolism for patient stratification and exploring its connection to tumor microenvironment (TME) remodeling. RNA sequencing data and independent datasets were integrated with predefined gene sets for DNA methylation (n = 79) and amino acid metabolism (n = 471). A analytical workflow was employed: identification of hub genes and least absolute shrinkage and selection operator (LASSO)-Cox modeling; construction of a prognostic nomogram; comprehensive TME profiling; and validation through single-cell RNA sequencing (scRNA-seq) cellular dynamics analysis and immunohistochemistry (IHC) on a prostate cancer tissue microarray. A novel six-gene prognostic model (ASPM, WDR86, CCK, HOXA2, EGF, ZFHX4) was developed. This model efficiently discriminates patients into groups based on risk level though divergent overall survival (p < 0.001) and exhibited high predictive accuracy in external validation sets (3-year area under the curve (AUC) = 0.87). A nomogram incorporating the signature, pathologic T stage, and Gleason score surpassed individual clinical factors (5-year AUC = 0.73). Functional annotation indicated that high-risk tumors were characterized by downregulated androgen response and activated E2F/G2M checkpoint pathways. The signature was correlated with an immunosuppressive TME, which was supported by a negative correlation between ZFHX4 and monocyte infiltration (r = -0.37, p < 0.001) and a positive correlation between ASPM and activated CD4
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.